パルテノリド
| 分子式： | C15H20O3 |
| その他の名称： | パルテノリド、Parthenolide、(1aR,4E,7aS,10aS,10bS)-2,3,6,7,7a,8,10a,10b-Octahydro-1a,5-dimethyl-8-methyleneoxireno[9,10]cyclodeca[1,2-b]furan-9(1aH)-one、4,5α-エポキシ-6β-ヒドロキシゲルマクラ-1(10),11(13)-ジエン-12-酸γ-ラクトン、(-)-パルテノリド、4,5α-Epoxy-6β-hydroxygermacra-1(10),11(13)-dien-12-oic acid γ-lactone、(-)-Parthenolide |
| 体系名： | (1aR,4E,7aS,10aS,10bS)-2,3,6,7,7a,8,10a,10b-オクタヒドロ-1a,5-ジメチル-8-メチレンオキシレノ[9,10]シクロデカ[1,2-b]フラン-9(1aH)-オン |
パルテノリド
出典: フリー百科事典『ウィキペディア（Wikipedia）』 (2018/02/04 20:24 UTC 版)
パルテノリド（Parthenolide、パルテノライド）は、ナツシロギク (Tanacetum parthenium) に含まれる植物由来のセスキテルペンラクトン (ゲルマクラノリド類、germacranolides) である。花や果実に多く含まれている。
- ^ Fermentek. “Parthenolide, pure”. 2006年6月26日時点のオリジナルよりアーカイブ。2010年11月5日閲覧。
- ^ López-Franco O, Hernández-Vargas P, Ortiz-Muñoz G, Sanjuán G, Suzuki Y, Ortega L, Blanco J, Egido J, Gómez-Guerrero C (2006). “Parthenolide modulates the NF-kappaB-mediated inflammatory responses in experimental atherosclerosis”. Arterioscler. Thromb. Vasc. Biol. 26 (8): 1864–70. doi:10.1161/01.ATV.0000229659.94020.53. PMID 16741149.
- ^ Feltenstein MW, Schühly W, Warnick JE, Fischer NH, Sufka KJ (2004). “Anti-inflammatory and anti-hyperalgesic effects of sesquiterpene lactones from Magnolia and Bear's foot”. Pharmacol. Biochem. Behav. 79 (2): 299–302. doi:10.1016/j.pbb.2004.08.008. PMID 15501305.
- ^ García-Piñeres AJ, Castro V, Mora G, Schmidt TJ, Strunck E, Pahl HL, Merfort I (2001). “Cysteine 38 in p65/NF-κB plays a crucial role in DNA binding inhibition by sesquiterpene lactones”. J. Biol. Chem. 276 (43): 39713-39720. doi:10.1074/jbc.M101985200. PMID 11500489.
- ^ Hehner SP, Hofmann TG, Dröge W, Schmitz ML (1999). “The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex”. J. Immunol. 163 (10): 5617-5623. PMID 10553091.
- ^ Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM (2001). “The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase”. Chem. Biol. 8 (8): 759-766. doi:10.1016/S1074-5521(01)00049-7. PMID 11514225.
- ^ Guzman ML, Rossi RM, Karnischky L, Li X, Peterson DR, Howard DS, Jordan CT (2005). “The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells”. Blood 105 (11): 4163–9. doi:10.1182/blood-2004-10-4135. PMC 1895029. PMID 15687234.
- ^ Zunino SJ, Ducore JM, Storms DH (2007). “Parthenolide induces significant apoptosis and production of reactive oxygen species in high-risk pre-B leukemia cells”. Cancer lett. 254 (1): 119–27. doi:10.1016/j.canlet.2007.03.002. PMID 17470383.
- ^ Guzman ML, Jordan CT (2005). “Feverfew: weeding out the root of leukaemia”. Expert Opin. Biol> Ther. 5 (9): 1147–52. doi:10.1517/14712598.5.9.1147. PMID 16120045.
- ^ Yip-Schneider MT, Nakshatri H, Sweeney CJ, Marshall MS, Wiebke EA, Schmidt CM (4 2005). “Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells”. Mol. Cancer Ther. 4 (4): 587-594. doi:10.1158/1535-7163.MCT-04-0215. PMID 15827332.
- ^ Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC, Becker MW, Bennett JM, Sullivan E, Lachowicz JL, Vaughan A, Sweeney CJ, Matthews W, Carroll M, Liesveld JL, Crooks PA, Jordan CT (2007). “An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells”. Blood 110 (13): 4427-4435. doi:10.1182/blood-2007-05-090621. PMC 2234793. PMID 17804695.
- ^ Shanmugam R, Kusumanchi P, Appaiah H, Cheng L, Crooks P, Neelakantan S, Peat T, Klaunig J, Matthews W, Nakshatri H, Sweeney CJ (2010). “A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF-kappaB and generating reactive oxygen species”. Int. J. Cancer.. doi:10.1002/ijc.25587. PMID 20669221.
- ^ Neelakantan S, Nasim S, Guzman ML, Jordan CT, Crooks PA (2009). “Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-κB inhibitor, DMAPT (LC-1)”. Bioorg. Med. Chem. Lett. 19 (15): 4346-4349. doi:10.1016/j.bmcl.2009.05.092. PMID 19505822.
- ^ Tiuman TS, Ueda-Nakamura T, Garcia Cortez DA, Dias Filho BP, Morgado-Díaz JA, de Souza W, Nakamura CV (2005). “Antileishmanial activity of parthenolide, a sesquiterpene lactone isolated from Tanacetum parthenium”. Antimicrob. Agents Chemother. 49 (1): 176–82. doi:10.1128/AAC.49.11.176-182.2005. PMC 538891. PMID 15616293.
- ^ Miglietta A, Bozzo F, Gabriel L, Bocca C (2004). “Microtubule-interfering activity of parthenolide”. Chem. Biol. Interact. 149 (2-3): 165–73. doi:10.1016/j.cbi.2004.07.005. PMID 15501437.
- ^ Yip KH, Zheng MH, Feng HT, Steer JH, Joyce DA, Xu J (2004). “Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-kappaB activity”. J. Bone Miner. Res. 19 (11): 1905–16. doi:10.1359/JBMR.040919. PMID 15476591.
- ^ Herout V, Souček M, and Šorm F (1959). “Parthenolide, another sesquiterpenic lactone with a ten-membered ring”. Chemistry and Industry: 1969.
- ^ T. R. Govindachari, B. S. Joshi and V. N. Kamat (1965). “Structure of parthenolide”. Tetrahedron 21 (6): 1509-1519. doi:10.1016/S0040-4020(01)98314-0.
- ^ A. S. Bawdekar, G. R. Kelkar and S. C. Bhattacharyya (1966). “Terpenoids LXXXIX absolute configuration of parthenolide”. Tetrahedron Lett. 7 (11): 1225-1227. doi:10.1016/S0040-4039(00)72397-5.
- ^ Andrew Quick and Donald Rogers (1976). “Crystal and molecular structure of parthenolide [4,5-epoxygermacra-1(10),11(13)-dien-12,6-olactone]”. J. Chem. Soc., Perkin Trans. 2: 465-469. doi:10.1039/P29760000465.
[続きの解説]
「パルテノリド」の続きの解説一覧
- 1 パルテノリドとは
- 2 パルテノリドの概要
- 3 関連項目
- パルテノリドのページへのリンク
